Rocketlab Slides to $54 as Neutron Slips to 2027 and the Q3 Loss Widens to $0.12 — Bulls Need $65

Rocket Lab (NASDAQ: RKLB) traded at $54.29 on Tuesday morning, down 7.76% from Monday’s close of $58.86, after briefly dropping to $53.33, a 9% loss. Monday’s regular session had lifted the stock $5.79, or 10.91%, on volume of 32.00 million shares, as investors positioned for the third-quarter report. The report came out after the bell, and the after-hours reaction reversed the move. RKLB traded at $56.24 after hours, down 4.5%, then slid to $54.42, down 7.54%, and $54.00 in overnight trading, down 8.26%, before the regular open confirmed the drop.

The past week has been one of the most volatile stretches in the stock’s history. On Thursday, November 5, RKLB fell 12.18% to close at $45.99 as a post-election sell-off in technology spread to high-growth names. On Friday, November 6, it jumped 15.4% without any company news, closing at $53.07, above its November 4 close. On Monday it rose another 10.91% to $58.86. Tuesday’s drop gives back most of that gain. The stock has moved more than 10% in either direction in four of the last five sessions.

The longer view is weak. RKLB was down 16% year to date through Monday’s close. It hit $151 in May, just before SpaceX’s June IPO, and has lost 64% from that peak. On October 30 it closed at $54.73, almost exactly where it trades today. The stock sits far below its 200-day moving average near $80, and on August 10, the day of the second-quarter report, it closed at $80.04.

At $54.29, Rocket Lab has a market value of $36.9 billion, based on 639.2 million common shares and 40.95 million preferred shares. That’s a large valuation for a company with trailing twelve-month revenue of $882.2 million and no operating profit.

This article’s thesis is that Rocket Lab’s business is executing well, but the stock trades on three things the business can’t control right now: Neutron’s launch date, share dilution, and interest rates. Revenue grew 73% and backlog jumped 52% in a single quarter. Yet Neutron slipped to 2027 without a firm date, the share count rose 23% in a year, and today’s hot US CPI pushed the 2-year Treasury yield up 19 basis points. The near-term bias is bearish while Neutron lacks a date. The upside target is $65, 19.7% above $54.29, which requires a firm Neutron schedule or a turn in rates.

Record $267.8 Million Revenue, Up 73%, Beats Its Own Guidance

The revenue line was strong. Rocket Lab’s third-quarter 2026 release showed record revenue of $267.8 million, up 73% from $155.1 million a year earlier and $34 million above the second quarter’s $234.1 million. That beat the company’s own guidance of $250 million to $265 million and the $257.18 million consensus forecast by 4.1%. It was Rocket Lab’s sixth straight quarter of record revenue.

The split shows where the growth comes from. Product revenue nearly doubled to $197.5 million from $104.0 million, driven by spacecraft builds for NASA, the US Space Force, Globalstar and Viasat. Service revenue rose 38% to $70.3 million from $51.0 million. By segment, Space Systems delivered $214.8 million, up 13.3% from the second quarter, which leaves Launch Services at $53.0 million. Space Systems now makes up 80% of the business.

The 2026 trajectory is steep. Revenue was $200.3 million in the first quarter, $234.1 million in the second and $267.8 million in the third. Nine-month revenue totals $702.2 million, up 66% from $422.1 million in the same period of 2025. Full-year 2025 revenue was $602 million, up 38%.

Fourth-quarter guidance points to another record. Rocket Lab expects revenue of $270 million to $290 million, above analyst expectations. At the $280 million midpoint, full-year 2026 revenue would reach $982.2 million, up 63% from 2025 and just short of $1 billion.

Execution on the spacecraft side backs up the revenue. Twelve Rocket Lab-built spacecraft have launched and are operating, including eight satellite platforms for Globalstar, twin NASA Mars science spacecraft for the ESCAPADE mission, a VICTUS HAZE spacecraft for the US Space Force and a spacecraft for Viasat’s NASA Communications Services Depot. More than 55 spacecraft are in development or production. Rocket Lab satellites and components have supported more than 1,700 missions in Earth orbit and deep space.

So revenue isn’t the problem. The issue is how that revenue converts to profit, and when Neutron adds its higher-margin launch revenue to the mix. Space Systems work, especially large defense constellation programs, carries lower margins than launch. As that segment grows faster, it pulls the overall margin down, and that’s the first crack in the report.

Backlog Jumps 52% in One Quarter to $3.57 Billion

The backlog is the strongest number in the report. Rocket Lab ended the third quarter with a record backlog of $3.57 billion, up 52%, or $1.2 billion, from the end of the second quarter. Backlog stood at $1.85 billion at the end of 2025 and $2.2 billion after the first quarter. It has nearly doubled in nine months.

New contracts drove the jump. Rocket Lab signed almost $1 billion in new launch contracts in the third quarter across Electron, HASTE and Neutron, and another $470 million for Space Systems. The total launch backlog now stands at 117 launches, a record. On the spacecraft side, more than 55 spacecraft are in development and build.

Neutron’s order book matters most. Constellation operators signed more than $515 million in Neutron launch contracts in the third quarter, bringing the rocket’s backlog to 16 missions before it has flown once. Rocket Lab raised its base launch price to $70 million for several of these missions, up from $55 million, as industry launch capacity tightens. That’s a 27% price increase on a rocket that hasn’t launched yet. Customers are paying more for Neutron slots because launch supply is scarce, and that pricing power is a key part of the long-term case.

Backlog conversion tells investors how quickly that order book turns into revenue. Rocket Lab expects 32.9% of its current backlog to convert into revenue within the next 12 months. On $3.57 billion, that’s $1.17 billion of revenue already contracted for the coming year. That figure is 19% higher than the full-year 2026 revenue estimate of $982.2 million, which suggests continued growth into 2027 even before new orders.

The other 67% of backlog, $2.4 billion, converts after 12 months. Much of that is tied to Neutron and multi-year spacecraft programs. That’s where Neutron’s timing becomes critical. Every month of delay pushes Neutron revenue further out and keeps a larger share of the backlog unconverted.

The market’s reaction shows investors aren’t paying for backlog alone. A 52% jump in backlog would normally send a growth stock higher. Instead, RKLB fell more than 7%. That tells you the market already expected strong orders and is now focused on what stands between the backlog and profit: Neutron’s launch, margins and cash burn. Backlog sets the ceiling for Rocket Lab’s future revenue. Neutron sets the timing.

Neutron Slips to “No Earlier Than 2027” With No Month Given

Neutron is the reason the stock is down. Rocket Lab confirmed that Neutron’s first launch is targeted for no earlier than 2027, and management gave no month or quarter. That’s the third major delay in the rocket’s history. Neutron was first targeted for mid-2025, then the fourth quarter of 2026, and now an unspecified point in 2027.

The cause of the latest delay is a manufacturing problem. In October, Rocket Lab found voids in parts of a composite propellant tank dome on the first stage. The issue prompted process changes and a replacement component. Rocket Lab first disclosed the slip to 2027 in mid-October, and the stock fell then. In January 2026, a first-stage tank ruptured during testing, another setback that pushed the timeline back. The company says work continues on assembly, integration, testing and delivery of first-flight hardware to Launch Complex 3, and the second stage and thrust structure have been shipped to Wallops Island for ground testing.

Neutron matters because it changes the economics of the whole company. Electron is a small rocket that carries small satellites. Neutron is a reusable medium-lift rocket that can carry much larger payloads, opening the door to commercial constellations, civil space and national-security missions. At $70 million per launch on a reusable rocket, Neutron should carry much higher margins than spacecraft manufacturing. It’s the product that’s supposed to turn Rocket Lab from a fast-growing, loss-making company into a profitable one.

The profit timeline depends on it directly. CFO Adam Spice said adjusted EBITDA should turn positive within six months of Neutron’s first successful flight. On the second-quarter call, he had said the quarter after the first successful test launch would mark the shift to adjusted EBITDA positivity, with cash flow positivity 18 to 24 months after that. With the first launch now in 2027 and no date set, EBITDA positivity likely shifts to the second half of 2027 at the earliest, and free cash flow positivity into 2028 or 2029.

That’s why the missing date hurt so much. Investors can value a delay if they know how long it is. They can’t value an open-ended one. Without a month, every model has to assume a range, and the stock gets priced near the conservative end. A firm launch date would remove that uncertainty and likely trigger a rally. Another slip would push the stock lower. Until then, Neutron is a binary risk the market discounts heavily.

Margins Compress: GAAP Gross Margin Falls to 33.6%

Profitability went the wrong way. GAAP gross margin was 33.6% in the third quarter, down from 37.0% a year earlier. Non-GAAP gross margin was 38.4%, down from 41.9%. Both beat the company’s guidance, 29% to 31% GAAP and 35% to 37% non-GAAP, but the year-over-year drop shows the mix shift is real.

The trend over 2026 is clear. GAAP gross margin hit a record 38.2% in the first quarter, fell to 36.1% in the second and 33.6% in the third. Non-GAAP gross margin was 43% in the first quarter and is now 38.4%. The decline comes from a higher share of lower-margin Space Systems work, especially large satellite platform programs for the Space Development Agency, and dilution from the newly acquired Monaric business in Germany.

Gross profit still grew. GAAP gross profit rose 57% to $90.1 million from $57.3 million, and non-GAAP gross profit rose 58% to $102.8 million from $65.0 million. Revenue growth is outrunning the margin squeeze. But each dollar of new revenue is earning less gross profit than a year ago, which makes the path to operating profit longer.

Fourth-quarter guidance offers some relief. Rocket Lab expects GAAP gross margin of 34% to 36% and non-GAAP gross margin of 39% to 41%, both a step up from the third quarter. The company’s headline described this as gross margin expansion. If delivered, it would end the three-quarter slide. The midpoint of 35% GAAP would still be below the 37.0% posted a year earlier.

The margin story is tied to Neutron. Space Systems will keep growing faster than launch until Neutron flies, because Electron is a small rocket with limited capacity. Satellite manufacturing at scale carries lower margins than launch, so margins will stay under pressure until Neutron adds high-margin launch revenue. That’s another reason the delay matters: it extends the period of compressed margins.

For investors, the gross margin line is the clearest read on business quality. A move back toward 37% to 38% GAAP would suggest the mix shift is stabilizing. A further slide below 33% would raise questions about whether Rocket Lab can earn the margins its valuation assumes. Fourth-quarter guidance points to stabilization, but the trend has to show up in results.

The Loss Widens: $79.7 Million Net Loss, EPS of −$0.12

The bottom line missed. Rocket Lab posted a net loss of $79.7 million, or $0.12 per share, compared with a loss of $18.3 million, or $0.03 per share, a year earlier. The consensus estimate was a $0.07 loss, so the GAAP loss was 80% wider than forecast. On an adjusted basis, the loss was $0.08 per share against a $0.07 consensus.

Two one-time items drove most of the miss. Rocket Lab recorded a $27.3 million loss on extinguishment of debt as it retired almost all of its convertible notes. Convertible senior notes fell to $1.3 million from $152.4 million at the end of 2025. It also booked $21.3 million in transaction costs for the pending Iridium acquisition in the third quarter, bringing the nine-month total to $31.6 million. Without those two items, the net loss would have been $31.1 million, or roughly $0.05 per share.

Operating expenses ran hot. GAAP operating expenses were $169.3 million, well above guidance of $143 million to $149 million and up 46% from $116.3 million a year earlier. Non-GAAP operating expenses were $130.2 million, modestly above guidance of $121 million to $127 million. The overrun came from Neutron development and Iridium transaction costs. GAAP operating loss widened to $79.2 million from $59.0 million.

On a non-GAAP basis, the operating picture improved. Non-GAAP operating loss narrowed to $27.4 million from $33.2 million. Adjusted EBITDA was a loss of $18.0 million, better than the $26.3 million loss a year earlier and toward the low end of guidance, a $17 million to $23 million loss. Interest income jumped to $28.6 million from $6.7 million thanks to the company’s large cash pile.

Fourth-quarter guidance calls for an adjusted EBITDA loss of $14 million to $20 million, a narrower loss than the third quarter, though wider than analysts had expected. GAAP operating expenses are guided to $162 million to $168 million and non-GAAP operating expenses to $136 million to $142 million. Interest income is expected to rise to $45 million.

Over nine months, Rocket Lab lost $174.0 million, or $0.28 per share, with an adjusted EBITDA loss of $38.6 million. The company is narrowing its adjusted losses, but GAAP results remain deep in the red. With Neutron delayed, adjusted EBITDA isn’t likely to turn positive before the second half of 2027.

A $4.7 Billion Cash Pile, Funded by Dilution

Rocket Lab has plenty of money. At September 30, cash and cash equivalents stood at $4.448 billion, up from $828.7 million at the end of 2025. Including $256.2 million in marketable securities, total cash and securities reached $4.704 billion. Debt is almost gone: convertible notes are down to $1.3 million and long-term borrowings to $1.7 million. Total assets are $6.57 billion against $766.1 million in liabilities.

That cash came from shareholders. In the first nine months of 2026, Rocket Lab raised $3.912 billion in gross proceeds through at-the-market equity sales, less $36.7 million in costs. That included a September financing of $1.944 billion from the sale of 29.3 million shares. The company used ATM equity to fully fund the pending Iridium acquisition.

The dilution is large. Weighted-average shares outstanding rose to 652.3 million in the third quarter from 528.7 million a year earlier, a 23% increase. Fourth-quarter guidance calls for 681 million basic weighted-average shares, including 41 million Series A convertible preferred shares, up another 4% from the third quarter. Each share now owns a smaller slice of the company than it did a year ago.

Here’s why that matters for the stock price. Revenue grew 73% in the third quarter, but revenue per share grew much less, because the share count rose 23%. Investors buying RKLB are paying for future profits per share, and dilution reduces those. Selling stock at high prices to build a cash reserve is a sound corporate strategy, but it caps how much existing shareholders benefit from growth.

Insider selling adds to the overhang. CEO Peter Beck sold shares totaling $286.4 million in July 2026. Insider sales don’t necessarily signal anything about the business, but large sales at higher prices make investors more cautious about buying at current levels.

Cash burn remains real. Nine-month operating cash flow was a $127.3 million outflow, and capital spending was $84.2 million, for nine-month free cash flow of negative $211.4 million. The company highlighted positive GAAP operating cash flow of $7.2 million for the third quarter alone, an improvement, though that figure can’t be verified from the nine-month tables. At a burn rate of roughly $280 million a year, the $4.7 billion cash pile gives Rocket Lab more than a decade of runway before Neutron revenue. Liquidity isn’t a risk. Dilution is the cost of that safety.

The Iridium Deal: A Pending Transformation

Rocket Lab is buying Iridium Communications, a satellite communications company with a global constellation and recurring subscription revenue. The deal is pending. Iridium shareholders gave overwhelming approval, and Iridium’s lenders agreed to keep its credit facility in place after the transaction. The deal is fully funded through Rocket Lab’s completed ATM equity offering. Regulatory approvals are still outstanding, and the release doesn’t state the purchase price.

The strategic logic is about owning the full chain. Rocket Lab already builds rockets and spacecraft. With Iridium, it would own an operating satellite network with paying customers. That moves the company from selling hardware and launch services to earning recurring service revenue from its own constellation, a model similar to how SpaceX built Starlink on top of its launch business.

The financial effect would be significant. Iridium carries debt of about $1.775 billion, which Rocket Lab would take on through the retained credit facility. Iridium generates steady cash flow from subscriptions, which would help offset Rocket Lab’s operating losses. It would also give Rocket Lab a large existing customer base for future spacecraft and launch services, as Iridium’s constellation will eventually need replacement satellites.

The costs are already showing up. Rocket Lab booked $21.3 million in Iridium transaction costs in the third quarter and $31.6 million over nine months. Those costs were a major reason GAAP operating expenses exceeded guidance. More integration costs will follow once the deal closes.

For the stock, Iridium adds both upside and execution risk. On the upside, recurring revenue would improve the quality of Rocket Lab’s earnings and make the company less dependent on Neutron’s timing. On the risk side, integrating a large telecom business while developing a new rocket and scaling spacecraft production stretches management. A delay in regulatory approval would extend the uncertainty.

The two biggest variables for the investment case are now Neutron’s schedule and the Iridium closing. Both are pending, both carry timing risk, and both will likely move the stock more than quarterly revenue in the coming months. A clean Iridium close would give investors a concrete positive while they wait for Neutron.

Valuation: 37.6x 2026 Sales Leaves No Room for Delay

At $54.29, Rocket Lab is priced for a future that hasn’t arrived yet. The company’s market value of $36.9 billion, based on 680.15 million common and preferred shares, compares with trailing twelve-month revenue of $882.2 million. That’s 41.8 times trailing sales. Subtracting $4.7 billion in cash and securities gives an enterprise value of $32.2 billion, or 36.5 times trailing sales.

Forward multiples are lower but still steep. On full-year 2026 revenue of $982.2 million, the company trades at 37.6 times sales on market value and 32.8 times on enterprise value. On the $1.17 billion of backlog expected to convert in the next 12 months, the enterprise value is 27.5 times forward contracted revenue.

Those multiples are high for a company with compressing gross margins and no operating profit. They only make sense if Neutron launches successfully, prices at $70 million or more per mission and lifts margins and earnings sharply in 2027 and 2028. Every month of delay shrinks the present value of that future. That’s why the open-ended 2027 timeline weighed so heavily on the stock.

Interest rates make the math harder. Today’s hot US CPI pushed the 2-year Treasury yield up 19 basis points to 4.736% and the 10-year toward 5%. Rocket Lab’s valuation depends on profits that are years away. When rates rise, the present value of those distant profits falls more than the value of near-term earnings. High-multiple stocks with long-dated earnings get hit hardest on days like today, and the Nasdaq Composite fell 0.87% in the same morning.

The stock’s history shows how sensitive it is to this. At its May peak of $151, RKLB traded at roughly three times its current valuation on lower revenue. The 64% drop since then reflects a combination of Neutron delays, rising rates and a broader sell-off in high-growth names. Revenue has grown strongly throughout, but the multiple has compressed far faster.

The valuation does have a floor. Rocket Lab holds $4.7 billion in cash, 13% of its market value, with almost no debt. Its contracted backlog of $3.57 billion is real revenue waiting to be delivered. And the price increase to $70 million per Neutron launch shows customers will pay a premium for capacity. Those factors limit the downside but don’t remove it. The stock needs a Neutron date to justify a higher multiple.

Space Stocks Fall Together: Peers Slide on the Same Rate Shock

Rocket Lab isn’t falling alone. Space stocks broadly sold off Tuesday as investors digested two quarterly reports that landed after Monday’s close. AST SpaceMobile (ASTS) fell 6% after a price-target cut, while SpaceX shares slid 3%. AST SpaceMobile also announced a deal worth more than $1 billion for Firefly Aerospace engines to power its homegrown Blacklift rocket, a sign that satellite operators are trying to secure their own launch capacity as supply tightens.

That last point supports Rocket Lab’s pricing power. If satellite companies are investing billions to build their own rockets, launch capacity is scarce. That’s consistent with Rocket Lab’s ability to raise Neutron’s base price to $70 million from $55 million. Scarcity in launch is a tailwind for any company that can deliver reliable medium-lift capacity. Rocket Lab’s challenge is getting Neutron to market before competitors fill the gap.

SpaceX’s presence in public markets has changed how investors value space stocks. SpaceX’s June IPO created a public benchmark for the sector. Rocket Lab hit its $151 high in May, just before that offering, as investors bid up space names in anticipation. Since then, capital that might have gone to smaller space companies has a large, proven alternative in SpaceX. That likely accounts for part of RKLB’s drawdown from its peak.

The broader market backdrop is a headwind for every high-growth name. On November 5, the S&P 500 fell 4.4%, its worst day since April 2025, and RKLB fell 12.18% the same day. On Monday, the S&P 500 jumped 2.35% and RKLB rose 10.91%. Today, the S&P 500 is down 0.71% and RKLB is down 7.76%. The stock is trading with a beta of more than two against the market, amplifying every macro move.

Redwire, another space company, reported a narrower third-quarter loss than expected but with revenue below forecasts on November 4, and its shares fell 19.8% on November 5. That pattern of space stocks falling hard on mixed results mirrors Rocket Lab today. The sector is in a phase where investors punish any miss, even with strong underlying growth.

Peer performance suggests RKLB’s drop is part macro, part sector and part company-specific. The rate shock and sector sell-off explain some of the decline. The Neutron delay, wider loss and margin compression explain the rest. A broad recovery in growth stocks would lift RKLB, but the stock would still need its own catalyst to outperform.

Technical Picture: $54 Is the Pivot, $45.99 the Floor

RKLB’s chart shows a stock caught in a wide, volatile range below a falling long-term trend. The 200-day moving average sits near $80, far above the current $54.29, and slopes down. The stock has traded below that line since the summer, confirming a long-term downtrend from the May peak at $151.

The near-term range is defined by the past week. The low is $45.99, Thursday’s close and the bottom of the post-election sell-off. The high is $58.86, Monday’s close before earnings. Tuesday’s drop puts the stock near the middle of that range. The $53 to $54 zone is the pivot. It matches Friday’s close at $53.07, October 30’s close at $54.73 and today’s intraday low at $53.33. Holding that zone would keep the stock in a sideways pattern. Breaking below it would point back toward $49.25, the post-earnings low after the second-quarter report, and then $45.99.

On the upside, Monday’s close at $58.86 is the first resistance level and marks the top of the recent bounce. Above that, $60 is a round-number barrier the stock approached but didn’t clear last week. A move through $60 would open a path to $64 and then $65, the upside target, which sits 19.7% above the current price. Beyond that, the August 10 close at $80.04 and the 200-day average near $80 mark the major long-term resistance.

Volatility is extreme. The stock has moved between $45.99 and $58.86, a 28% range, in four sessions. Daily swings of 10% or more are now routine. That makes stop placement difficult and suggests options markets are pricing high implied volatility. For traders, that volatility cuts both ways. A firm Neutron date could send the stock up 15% to 20% in a day. Another delay could drop it 15% just as fast.

The pattern after earnings has also been negative. RKLB has historically fallen after more than half of its earnings beats. After the August 10 report, the stock drifted 15.7% lower over the following weeks. If that pattern holds, today’s drop could extend toward $49.25 before the stock finds a base.

Volume confirms the move. Monday’s rally came on 32 million shares, a heavy session. Tuesday’s selling is reversing that gain, which suggests the pre-earnings buyers are taking profits rather than holding through uncertainty.

Catalysts Ahead: Neutron Date, Iridium Close and the Fed

Several events will decide where RKLB goes from here. The most important is a firm Neutron launch date. Rocket Lab has said only “no earlier than 2027.” Any update that names a quarter or month would remove the biggest source of uncertainty. Milestones to watch include completion of the replacement tank dome, integrated ground testing at Wallops Island, and a static fire of the full vehicle at Launch Complex 3. Each would show progress toward a date.

The Iridium acquisition is the second catalyst. The deal has shareholder and lender approval and full funding. Regulatory approval is the remaining step. A clean close would give Rocket Lab recurring subscription revenue and a concrete positive while investors wait for Neutron. A regulatory delay or added conditions would extend uncertainty and could weigh on the stock.

Fourth-quarter results, due in late February 2027, will test whether guidance holds. The company expects revenue of $270 million to $290 million, GAAP gross margin of 34% to 36% and an adjusted EBITDA loss of $14 million to $20 million. Hitting the top end of revenue guidance while expanding margins would show the business is stabilizing. Missing on margins would reinforce concerns about mix.

New contracts will continue to matter. Rocket Lab signed $1 billion in launch contracts and $470 million in Space Systems contracts in the third quarter. More defense awards, especially tied to the Space Development Agency or the Golden Dome missile defense program, would support the backlog. More Neutron contracts at $70 million or higher would confirm pricing power.

Macro events will also drive the stock. Friday’s producer-price report, the Fed minutes on November 18, PCE inflation later in November and the Fed’s December 9 decision will all move rates. With the Fed debating a half-point hike and odds of a 50-basis-point move at 15%, any hawkish surprise would hurt high-multiple growth stocks like RKLB. A dovish surprise would help.

Electron launch cadence is a smaller but steady factor. Each successful Electron and HASTE mission adds to revenue and reinforces Rocket Lab’s reliability record. Any Electron failure would be a major setback for both revenue and confidence in Neutron.

Scenarios, Levels and the Verdict for RKLB

RKLB’s near-term path runs through three levels: $45.99, $58.86 and $65.

The bearish scenario starts with a close below $53. That would break the pivot zone formed by Friday’s close, October 30’s close and today’s low. The next target would be $49.25, the post-earnings low after the second-quarter report, followed by $45.99, last Thursday’s close. Triggers include another hawkish US data surprise on Friday or later in November, a further slide in high-growth stocks, any hint of a further Neutron slip, a regulatory delay on Iridium, or more dilution through additional share sales. In that scenario, the stock’s high beta would amplify market weakness.

The base case is a range between $49.25 and $60 into year-end. The backlog, cash pile and fourth-quarter revenue guidance would support the stock near $50, while the open-ended Neutron timeline and compressed margins would cap rallies near $60. The stock would swing sharply with the market, as it has all month, without breaking out.

The bullish scenario needs a catalyst. A firm Neutron launch date, a clean Iridium close or a decline in Treasury yields after soft inflation data could each trigger a rally. RKLB would first need to reclaim Monday’s close at $58.86, then clear $60. That would open a path to $64 and then the $65 upside target, 19.7% above $54.29. A sustained move above $65 would require Neutron to move from testing toward a launch date, which would let investors begin pricing in 2027 Neutron revenue at $70 million per mission.

The verdict is bearish in the near term, with $65 as the upside target. Rocket Lab delivered a strong quarter on the top line: record revenue of $267.8 million, up 73%, a backlog that jumped 52% to $3.57 billion, 16 Neutron missions sold at prices up to $70 million, and $4.7 billion in cash with almost no debt. But the stock trades on Neutron, and Neutron now has no launch date beyond “no earlier than 2027.” GAAP gross margin fell to 33.6%, the net loss widened to $79.7 million, the share count rose 23% in a year, and today’s rate shock hit high-multiple growth stocks hardest. At 37.6 times 2026 sales, the valuation leaves no room for delay. A test of $49.25 is more likely than a run to $65 until Neutron gets a firm date. A close above $60 would invalidate the bearish view and put $65 in play.

That's TradingNEWS